Anichini, Andrea

Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study

Necchi, A., Anichini, A., Raggi, D., Briganti, A., Massa, S., Lucianò, R., Colecchia, M., Giannatempo, P., Mortarini, R., Bianchi, M., et al. (2018) · Journal of Clinical Oncology

Bladder and Urothelial Cancer TreatmentsCancer Immunotherapy and Biomarkers

Cited by 741

NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo

Lakshmikanth, T., Burke, S., Ali, T. H., Kimpfler, S., Ursini, F., Ruggeri, L., Capanni, M., Umansky, V., Paschen, A., Sucker, A., et al. (2009) · Journal of Clinical Investigation

Immune Cell Function and InteractionImmunotherapy and Immune Responses

Cited by 347

Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma

Sensi, M., Nicolini, G., Petti, C., Bersani, I., Lozupone, F., Molla, A., Vegetti, C., Nonaka, D., Mortarini, R., Parmiani, G., et al. (2006) · Oncogene

Melanoma and MAPK PathwaysNeurofibromatosis and Schwannoma Cases

Cited by 183

An open-label, single-group, phase 2 study of brentuximab vedotin as salvage therapy for males with relapsed germ-cell tumors (GCT): Results at the end of first stage (FM12GCT01).

Necchi, A., Magazzu, D., Anichini, A., Raggi, D., Giannatempo, P., Nicolai, N., Colecchia, M., Paolini, B., Coradeschi, E., Tassi, E., et al. (2016) · Journal of Clinical Oncology

Testicular diseases and treatmentsLymphoma Diagnosis and Treatment

Cited by 17